Login
$LAB
$0.60 -$0.11 (15.04%) Live

$LAB 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Other Events

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

03 Nov 2026 8-K: Regulation FD Disclosure

ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific

05 Oct 2026 8-K: Regulation FD Disclosure

Boston, Mass., October, 5, 2026 – Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leadi...

30 Sep 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

05 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOSTON, Mass., August 5, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026.

28 Jul 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This TERMINATION, WAIVER AND RELEASE AGREEMENT (this “Agreement”) is made as of July 24, 2026, by and between Illumina, Inc., a Delaware corporation (“Purchaser”), and Standard BioTools Inc., a Delaware corporation (“Seller” and, togethe...

24 Jul 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 22, 2026, Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that t...

18 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The purposes of this Plan are (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide additional incentive to Employees, Directors, and Consultants, and (c) to promote the succes...

08 Jun 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +3 more

This Contingent Value Rights Agreement (this “Agreement”), dated as of [●] (the “Effective Date”), is entered into by and between Treeline Biosciences Holdings, Inc., a Delaware corporation (“Parent”), and [●], a [●], as Rights Agent (as...

05 Jun 2026 8-K: Other Events

On June 5, 2026, Standard BioTools Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it has regained compliance with Nasdaq Listing R...

03 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On May 29, 2026, the Human Capital Committee of the Board of Directors of Standard BioTools Inc. (the “Company”) approved a grant of 500,000 restricted stock units for Sean Mackay, Chief Business Officer of the Company, under the Company...

28 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

Introduction. The purpose of this Standard BioTools Inc. 2026 Change of Control and Severance Plan, or Plan (as defined in Section 2 below), is to provide assurances of specified benefits to certain employees of the Company whose employm...

05 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOSTON, Mass., May 5, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026.

24 Apr 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On April 20, 2026, Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that ...

24 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOSTON, Mass., February 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025.

30 Jan 2026 8-K: Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition +1 more

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments

08 Jan 2026 8-K: Results of Operations and Financial Condition

Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 million

04 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

SOUTH SAN FRANCISCO, Calif., November 4, 2025 -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended September 30, 2025.

17 Sep 2025 8-K: Costs Associated with Exit or Disposal Activities

On September 13, 2025, Standard BioTools Inc. (the “Company”) commenced a restructuring plan, including a reduction-in-force of approximately 15% of its total global workforce. The purpose of this restructuring plan, including the reduct...

03 Sep 2025 8-K: Costs Associated with Exit or Disposal Activities

On August 28, 2025, Standard BioTools Inc. (the “Company”) determined to consolidate its South San Francisco-based R&D capabilities into its Singapore facility to co-locate with its manufacturing operations and to implement a reduction-i...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support